Daclatasvir

Description

Daclatasvir is an antiviral medication used for the treatment of chronic hepatitis C in adults. It is normally used in a combination with sofosbuvir, with or without ribavirin. However, this medicine is not recommended for use as a preventive option for the spread of hepatitis C.

Side effects

Major & minor side effects for Daclatasvir

  • Headache
  • Unusual tiredness
  • Nausea and Vomiting
  • Diarrhea
  • Anemia
  • Severe skin rash and hives
  • Dizziness
  • Sleep disturbances
  • Shortness of breath
  • Chest pain or discomfort
  • Mental confusion
  • Memory problems

Uses of Daclatasvir

What is it prescribed for?

  • Chronic Hepatitis C
Read More
Concerns

Commonly asked questions

  • Onset of action
    The peak effect of this medicine can be observed within 2 hours of administration of the dose.
  • Duration of effect
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Safe with alcohol?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?
    No habit-forming tendencies were reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.

Allergy

This medicine is not recommended for use in patients with a known allergy to daclatasvir, any other medicine used along with it as a part of combination therapy, or any other inactive ingredient present along with it. Contraindications of the individual medicines which are used along with daclatasvir as combinational therapy should also be considered before beginning treatment.

Strong CYP3A inducers

This medicine is not recommended for use in patients receiving strong CYP3A inducers such as phenytoin, carbamazepine, rifampin, St.John’s wort, etc. due to the increased risk of worsening of the patient’s condition.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.
General warnings

Other medicines

Daclatasvir may interact with many other medicines and may cause severe adverse effects. Hence, it is advised that you inform the doctor about all your current medicines including any herbs and supplements before beginning treatment with this medicine.

Hepatitis B reactivation

Use of this medicine in patients who also have hepatitis B may cause viral reactivation and potentially life-threatening side effects. Hence, it is advised to screen patients for hepatitis B infection before beginning therapy with this medicine.

Change in heart rate

Use of this medicine in a combination with sofosbuvir and amiodarone may increase the risk of decreased heart rate. This risk is especially higher in patients suffering from cardiac disorders and patients who are receiving beta blockers. An alternative treatment option may be necessary in some cases based on the clinical condition.

Tests prior to initiation of therapy

You may require to undergo certain tests like NS5A resistance testing in HCV genotype 1a- infected patients with cirrhosis before initiation of therapy.

Kidney impairment

This medicine should be used with caution in patients with kidney diseases due to the increased risk of severe adverse effects. Regular monitoring of kidney function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Liver impairment

This medicine should be used with caution in patients with liver diseases due to the increased risk of severe adverse effects. Regular monitoring of liver function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Use in children

This medicine is not recommended for use in patients less than 18 years of age since the safety and efficacy of use are not clinically established.

Limitation of use

Sustained virologic response (SVR12) rates are reduced in HCV genotype 3- infected patients with cirrhosis receiving this medicine in a combination with sofosbuvir for 12 weeks. An alternative treatment option may be necessary in such cases based on the clinical condition of the patient.

Driving or Operating machinery

Use of this medicine may cause symptoms such as dizziness, confusion, etc. in some patients. It is advised that you do not perform any activities such as driving a vehicle or operating machinery if you experience any of these symptoms during treatment with this medicine.

Missed Dose

Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double your dose to make up for the missed one.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Dexamethasone

Atazanavir

Bosentan

Modafinil

Dabigatran

Efavirenz

Nevirapine

Digoxin

Clarithromycin

Ketoconazole

Atorvastatin

Disease interactions

Hepatitis B

In patients coinfected with hepatitis B and hepatitis C virus, the use of this medicine may cause a reactivation of HBV, causing life-threatening events. Hence, testing the patients for hepatitis B before initiating the treatment course with this medicine is recommended. An alternative treatment option may be necessary in some cases based on the clinical condition.
Food interactions
Information not available.
Lab interactions
Information not available.
Take this medicine with or without food. Do not take in larger or smaller amounts than advised/prescribed. Consult the doctor if you experience any undesirable side effects. Ensure that the course of treatment is completed. Do not stop the use of this medicine without consulting your doctor. It is advised to continue the uptake of this medicine, even when symptoms resolve or improve until the therapy is completed.
Miscelleneous

Can be taken with or without food, as advised by your doctor

To be taken as instructed by doctor

May cause sleepiness

How it works
This medicine works by preventing the multiplication of hepatitis C virus in the body.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

NS5A inhibitors

Schedule

Schedule H

[Internet]. Packageinserts.bms.com. 2018 [cited 20 August 2018]. Available from:

https://packageinserts.bms.com/pi/pi_daklinza.pdf

Daclatasvir - DrugBank [Internet]. Drugbank.ca. 2018 [cited 20 August 2018]. Available from:

https://www.drugbank.ca/drugs/DB09102

DailyMed - Daclatasvir tablet [Internet]. Dailymed.nlm.nih.gov. 2018 [cited 20 August 2018]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9803a6ff-8a3e-4c64-b3d0-7825c7123bf2#ID_c9493748-799b-4e72-987d-8e39e85ead8c

How will this medicine affect me?

Consult top doctors online and get an answer now
Chat now
Chat now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now
Book now
Something doesn’t feel right?
Report an error

Information on this page was last updated on 26 Dec 2018

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.